HSBC trading unit hit by $355m of XVA costs in H1

- By Abdool Fawzee Bhollah and Louie Woodall
- 03 Aug 2020

Adverse adjustments to the valuation of non-cleared derivatives (XVAs) at HSBC continued to sap earnings over the three months to end-June. Over the first six months of the year, credit valuation adjustments (CVA) and funding valuation adjustments (FVA) have lopped a combined $355 million off of income.

The hit was recorded at the UK firm’s global banking and markets (GB&M) division, and was

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to print this content. Please contact info@risk.net to find out more.

You are currently unable to copy this content. Please contact info@risk.net to find out more.

As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.

If you would like to purchase additional rights please email info@risk.net

You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.

If you would like to purchase additional rights please email info@risk.net